Previous Close | 130.12 |
Open | 131.72 |
Bid | 126.00 x 800 |
Ask | 134.68 x 900 |
Day's Range | 128.98 - 130.92 |
52 Week Range | 99.14 - 133.10 |
Volume | |
Avg. Volume | 8,287,572 |
Market Cap | 329.598B |
Beta (5Y Monthly) | 0.40 |
PE Ratio (TTM) | 145.19 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 3.08 (2.37%) |
Ex-Dividend Date | Mar 14, 2024 |
1y Target Est | N/A |
RAHWAY, N.J., April 29, 2024--Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults
RAHWAY, N.J., April 25, 2024--Merck Announces First-Quarter 2024 Financial Results
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced that Health Canada has granted approval of KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with fluoropyrimidine- and platinum-containing-chemotherapy, for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma. This approval is based on the results from the Phase 3 KEYNOTE-859 trial, whic